EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:29608 - isoformononetin
| Formula | C16H12O4 |
| Net Charge | 0 |
| Average Mass | 268.268 |
| Monoisotopic Mass | 268.07356 |
| SMILES | COc1ccc2c(=O)c(-c3ccc(O)cc3)coc2c1 |
| InChI | InChI=1S/C16H12O4/c1-19-12-6-7-13-15(8-12)20-9-14(16(13)18)10-2-4-11(17)5-3-10/h2-9,17H,1H3 |
| InChIKey | LNIQZRIHAMVRJA-UHFFFAOYSA-N |
| Roles Classification |
|---|
| Biological Roles: | apoptosis inhibitor Any substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms. metabolite Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| Application: | bone density conservation agent An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| isoformononetin (CHEBI:29608) has functional parent daidzein (CHEBI:28197) |
| isoformononetin (CHEBI:29608) has role apoptosis inhibitor (CHEBI:68494) |
| isoformononetin (CHEBI:29608) has role bone density conservation agent (CHEBI:50646) |
| isoformononetin (CHEBI:29608) has role metabolite (CHEBI:25212) |
| isoformononetin (CHEBI:29608) is a 7-methoxyisoflavones (CHEBI:140356) |
| isoformononetin (CHEBI:29608) is a hydroxyisoflavone (CHEBI:38755) |
| IUPAC Name |
|---|
| 3-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one |
| Synonyms | Source |
|---|---|
| 4'-Hydroxy-7-methoxyisoflavone | HMDB |
| 7-O-methyldaidzein | ChEBI |
| 4'-Hydroxy-7-methoxyisoflavone | KEGG COMPOUND |
| Manual Xrefs | Databases |
|---|---|
| C12125 | KEGG COMPOUND |
| HMO | PDBeChem |
| DB04202 | DrugBank |
| LMPK12050039 | LIPID MAPS |
| HMDB0033994 | HMDB |
| CPD-3343 | MetaCyc |
| C00009382 | KNApSAcK |
| Registry Numbers | Sources |
|---|---|
| Reaxys:251318 | Reaxys |
| CAS:486-63-5 | HMDB |
| Citations |
|---|